No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
FGEN FibroGen
- 1.195
- +0.055+4.82%
Trading Apr 23 11:09 ET
118.03MMarket Cap-409P/E (TTM)
1.260High1.100Low483.80KVolume1.150Open1.140Pre Close586.44KTurnover0.58%Turnover RatioLossP/E (Static)98.77MShares19.47052wk High-0.58P/B99.17MFloat Cap0.33352wk Low--Dividend TTM82.99MShs Float68.550Historical High--Div YieldTTM14.04%Amplitude0.333Historical Low1.212Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Kind Pharmaceuticals-Parties Agreed to Withdraw All Pending Legal Proceedings Between Them Regarding Hif-Phi Technology,Without Payment by Either Party
Express News | Kind Pharmaceuticals-Resolution of Dispute With FibroGen Was Regarding Co's Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Technology
Express News | Kind Pharmaceuticals-Hangzhou Andao Pharmaceutical, Co Announced a Resolution of Their Recent Dispute With FibroGen
Kind Pharmaceuticals Announces Settlement
HANGZHOU, China, April 16, 2024 /PRNewswire/ -- Today, Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC ("Kind Pharmaceuticals"), together with its Chief Executive Officer Dr. Dong Liu
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
Comments
🎯 Ph 3 readouts in Q2 2024...
$Travere Therapeutic(TVTX.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
$CG Oncology(CGON.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
17
📣 Ahead of AACR24, which starts this Friday, 🔬
here are 6 cancer readouts to watch this quarter:
$ImmunityBio(IBRX.US$ : Anktiva ▻ PDUFA ▻ Bladder CA
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib ▻ PDUFA ▻ Glioma
$GlycoMimetics(GLYC.US$ : Uproleselan ▻ Ph3 ▻ AML
$FibroGen(FGEN.US$ : Pamrevlumab ▻ Ph3 ▻ Pancreatic CA
$Viracta Therapeutics(VIRX.US$ : Nana-val ▻ Ph3 ▻ Lymphoma
here are 6 cancer readouts to watch this quarter:
$ImmunityBio(IBRX.US$ : Anktiva ▻ PDUFA ▻ Bladder CA
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib ▻ PDUFA ▻ Glioma
$GlycoMimetics(GLYC.US$ : Uproleselan ▻ Ph3 ▻ AML
$FibroGen(FGEN.US$ : Pamrevlumab ▻ Ph3 ▻ Pancreatic CA
$Viracta Therapeutics(VIRX.US$ : Nana-val ▻ Ph3 ▻ Lymphoma
5
Biotech Stock Catalyst Watchlist
🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies(ITCI.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$Hutchmed (China)(HCM.US$ Phase 3
$Viracta Therapeutics(VIRX.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Marinus Pharmaceuticals(MRNS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3...
$Intra-Cellular Therapies(ITCI.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$Hutchmed (China)(HCM.US$ Phase 3
$Viracta Therapeutics(VIRX.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Marinus Pharmaceuticals(MRNS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3...
15
Dr. Adib's appointment, with his vast oncology drug development experience, is viewed as a crucial step to speed up FibroGen's oncology pipeline and deliver innovative cancer treatments. His leadership is anticipated to aid the company's ongoing and future clinical development activities.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg